Glycan-interacting compounds and methods of use

Abstract

The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.

The invention claimed is: 
     
       1. A method of reducing tumor volume comprising administering an antibody that specifically binds to sialyl Tn antigen (STn) to a subject, wherein said subject has a tumor comprising STn, wherein said antibody is administered at a dose of from about 0.25 mg/kg to about 25 mg/kg, and wherein said antibody comprises:
 a heavy chain variable domain (VH) comprising:
 a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 143 81: 
 a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84; and 
 a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96; 
 
 a light chain variable domain (VL) comprising:
 a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108; 
 a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and 
 a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and 
 
 a conjugated cytotoxic agent, 
 
       thereby reducing the volume of said tumor comprising STn in said subject. 
     
     
       2. The method of  claim 1 , wherein said antibody is a monoclonal antibody. 
     
     
       3. The method of  claim 1 , wherein said antibody comprises an IgG1 isotype. 
     
     
       4. The method of  claim 1 , wherein said antibody comprises an IgG2 isotype. 
     
     
       5. The method of  claim 1 , wherein said conjugated cytotoxic agent comprises monomethyl auristatin E. 
     
     
       6. The method of  claim 1 , wherein tumor volume in said subject is reduced by at least 20%. 
     
     
       7. The method of  claim 6 , wherein tumor volume in said subject is reduced by from about 80% to about 99%. 
     
     
       8. The method of  claim 7 , wherein said conjugated cytotoxic agent comprises monomethyl auristatin E. 
     
     
       9. A composition comprising:
 (a) an antibody that specifically binds to sialyl Tn antigen (STn), said antibody comprising:
 a VH comprising:
 a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 143 81; 
 a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84; and 
 a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96; and 
 
 a VL comprising:
 a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108; 
 a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and 
 a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and 
 
 
 (b) an excipient, said excipient comprising from about 2 mM to about 100 mM citrate and from about 10 mM to about 300 mM NaCl. 
 
     
     
       10. The composition of  claim 9 , wherein said antibody is conjugated to a drug. 
     
     
       11. A method of treating cancer that expresses sialyl Tn antigen (STn) comprising administering a composition to a subject, wherein said subject comprises at least one cancer cell that expresses STn, and wherein said composition comprises:
 (a) an antibody that specifically binds to STn comprising:
 a VH comprising:
 a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 143 81; 
 a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84; and 
 a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96; 
 
 a VL comprising:
 a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108; 
 a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and 
 a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and 
 
 a conjugated cytotoxic agent; and 
 
 (b) an excipient, said excipient comprising from about 2 mM to about 100 mM citrate and from about 10 mM to about 300 mM NaCl, 
 
       thereby treating said cancer in said subject. 
     
     
       12. The method of  claim 11 , wherein said conjugated cytotoxic agent comprises monomethyl auristatin E. 
     
     
       13. The method of  claim 1 , wherein STn is present on the surface of at least one cell of said tumor comprising STn. 
     
     
       14. The method of  claim 11 , wherein STn is present on the surface of said at least one cancer cell that expresses STn. 
     
     
       15. A method of treating cancer that expresses sialyl Tn antigen (STn) comprising administering an antibody that specifically binds to STn to a subject, wherein said subject includes at least one cancer cell that expresses cell surface STn, wherein said antibody is administered at a dose of from about 0.25 mg/kg to about 25 mg/kg, and wherein said antibody comprises:
 a VH comprising:
 a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 143 81; 
 a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84; and 
 a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96; 
 
 a VL comprising:
 a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108; 
 a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and 
 a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and 
 
 wherein said antibody comprises an Fc region capable of promoting antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell phagocytosis, and/or complement-dependent cytotoxicity directed against said at least one cancer cell in said subject or wherein said antibody includes a conjugated cytotoxic agent, 
 
       thereby treating said cancer in said subject. 
     
     
       16. The method of  claim 15 , wherein said antibody includes a conjugated cytotoxic agent, wherein said conjugated cytotoxic agent is conjugated directly or via a linker. 
     
     
       17. The method of  claim 16 , wherein said conjugated cytotoxic agent comprises a cytoskeletal inhibitor. 
     
     
       18. The method of  claim 17 , wherein said cytoskeletal inhibitor is monomethyl auristatin E. 
     
     
       19. The composition of  claim 10 , wherein said drug is conjugated directly or via a linker. 
     
     
       20. The composition of  claim 19 , wherein said drug is a cytotoxic agent. 
     
     
       21. The composition of  claim 20 , wherein said cytotoxic agent is monomethyl auristatin E.